An NK cell ther­a­py biotech pulls IPO am­bi­tions weeks af­ter sec­ond tri­al clear­ance

Arti­va Bio­ther­a­peu­tics has elect­ed not to move for­ward with an IPO. The San Diego cell ther­a­py de­vel­op­er qui­et­ly dis­closed its plans not to wade in­to the murky pub­lic wa­ters in an SEC fil­ing on Tues­day.

With an IND clear­ance for its sec­ond on­col­o­gy as­set just six weeks ago, Arti­va has de­cid­ed to back out of its plans, which have been in the mak­ing since ear­ly 2021. The nat­ur­al killer, or NK, cell ther­a­py com­pa­ny orig­i­nal­ly pen­ciled in a $100 mil­lion of­fer­ing in April 2021, less than a full year af­ter com­ing out of stealth with $78 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER